The Lancet Respiratory Medicine: US patients face significant barriers in accessing adequate care for chronic lung disease

May 13, 2016

Despite being the third leading cause of death in the USA, people with chronic obstructive pulmonary disease (lung disease) face significant challenges in accessing care, with treatment costs remaining out of reach for many, and hospitals failing to provide recommended standards of care, according to a new report commissioned by The Lancet Respiratory Medicine journal, presented at the American Thoracic Society conference in San Francisco [1].

Written by 28 leading US experts in the field of respiratory health, the Commission provides the first comprehensive look at COPD care in the USA by interviewing patient representatives, caregivers, health-care providers, insurance and pharmaceutical companies to identify the challenges patients face on a daily basis, and how these could be resolved.

"This report reveals a real patchwork of care for patients with chronic obstructive pulmonary disease. The disease is the third leading cause of death in the USA, and disproportionately affects some of society's most vulnerable people, yet many patients lack access to basic therapies to improve their quality of life," says Dr MeiLan K Han, lead author of the Commission from the University of Michigan, Ann Arbor, MI, USA. "As a physician, I can discuss best treatments with my patients, only to later find out it isn't covered by their insurance, or the co-pay is simply too high. This report aims to move us from debating what ideal care could look like, back to a discussion of what patients are actually facing on a day to day basis." [2]

Chronic obstructive pulmonary disease (COPD) is an umbrella term used to describe progressive lung diseases including emphysema and chronic bronchitis. People with COPD suffer from increasing breathlessness and treatment usually includes drugs such as inhalers and pulmonary rehabilitation. COPD can be due to a number of factors, including smoking but also other environmental causes such as prolonged exposure to wood smoke or air pollution.

About 15 million adults (6.5% of the population) in the USA have a diagnosis of COPD, but some studies have found that up to 28.9 million people have evidence of pulmonary obstruction, suggesting that over half of Americans with COPD are undiagnosed. The disease disproportionately affects people from lower socio-economic backgrounds and older adults.

Although access to drugs such as inhalers has improved, the report finds that patients may face co-payments of $75 or more per drug. As a result, many patients report skipping days, not taking full dosages, or not collecting refills. Among patients with COPD, only half of medication doses are taken as prescribed. By comparison, up to three quarters of medication doses are correctly taken for other chronic diseases, such as diabetes, hypertension and heart disease (figure 4). The high cost of COPD drugs is partly because there are no generic inhalers licenced for use in the US.

In addition, pulmonary rehabilitation is repeatedly described by patients as the most helpful intervention in terms of improving their quality of life. But access is still limited because of a shortage of programmes that are geographically convenient for patients, and variable insurance coverage.

Every year, over 10 million physician visits, 1.5 million emergency department visits, and nearly 700000 hospital stays are linked to COPD. One in 5 hospital admissions for COPD are readmitted within a month, putting a huge strain on resources. The Commission also highlights poor standards of care, as only 1 in 3 hospital admissions offered patients the standard recommended treatments. They add that the absence of written protocols for inpatients, as has already been established for other diseases, has led to COPD being a low priority in hospital.

Recent requirements by Medicare have focused on reducing the rates of hospital re-admission, but the report authors say most re-admissions for COPD are due to poor access to care or support outside hospital, and that preventing admission in the first place through improved diagnosis, access to treatment and care should be a priority.

The authors say that caring for patients will require better education for patients and physicians to improve diagnosis and treatment. They add that better coordinated action among insurers, the pharmaceutical industry and physicians is needed to reduce the financial burden on patients which could in turn increase adherence to medicines, and ultimately reduce overall healthcare spending.

Finally, the author say that more research is needed to understand the disease and develop new treatments. Unlike other chronic diseases where the amount of funding more or less matches the burden of the disease, COPD ranks 14th most funded research category by the National Institutes of Health (NIH), despite being the third leading cause of death in the USA (figure 5).
-end-


NOTES TO EDITORS


[1] The conference runs from 13-17 May. The Lancet Respiratory Medicine report will be presented on Tuesday 17th May at https://cms.psav.com/ats2016/planner/%22The%20Lancet%22

[2] Quote direct from the author and cannot be found in the text of the Commission.

The Lancet

Related COPD Articles from Brightsurf:

Promising therapeutic approach against COPD
Chronic obstructive pulmonary disease (COPD) is one of the most common and deadliest diseases worldwide.

COPD underdiagnosed in older adults, but can be managed
''Recognizing and Treating COPD in Older Adults'' the latest issue of the What's Hot newsletter from The Gerontological Society of America, addresses what is known about the prevalence, incidence, and impact of chronic obstructive pulmonary disease (COPD) in older adults.

Undersized airways may explain why nonsmokers get COPD
A mismatch between airway and lung size may explain why some nonsmokers get COPD and some heavy smokers do not, according to a new study from Columbia University Irving Medical Center.

Is pulmonary rehab after hospitalization for COPD associated with better survival?
Claims data for nearly 200,000 Medicare patients were used to examine the association between starting pulmonary rehabilitation within 90 days of being hospitalized for chronic obstructive pulmonary disease (COPD) and survival after one year.

COPD and smoking associated with higher COVID-19 mortality
Current smokers and people with chronic obstructive pulmonary disease (COPD) have an increased risk of severe complications and higher mortality with COVID-19 infection, according to a new study published May 11, 2020 in the open-access journal PLOS ONE by Jaber Alqahtani of University College London, UK, and colleagues.

COPD as a lung stem cell disease
Two internationally renowned stem cell researchers at the University of Houston have found an abundance of abnormal stem cells in the lungs of patients who suffer from Chronic Obstructive Pulmonary Disease (COPD), a leading cause of death worldwide.

New hope for COPD patients possible with in-home device
In a new paper published Feb. 4 in JAMA, Mayo Clinic researchers describe the benefits of in-home noninvasive ventilation therapy, which includes a type referred to as bilevel positive airway pressure, or BiPAP -- for many patients with chronic obstructive pulmonary disease (COPD).

COPD appears to cause more severe symptoms in women
Women who develop COPD report smoking fewer cigarettes than men; and yet, women experience greater breathing impairments, are subjected to more acute exacerbations of symptoms and report lower quality of life than men with the disease, according to research presented at ATS 2019.

African-Americans with COPD appear less likely to use pulmonary rehab
African-American patients with chronic obstructive pulmonary disease, or COPD, are less likely to participate in pulmonary rehabilitation programs than white patients, even when there are programs nearby.

COPD and type 2 diabetes
COPD and type 2 diabetes are two highly prevalent global health conditions associated with high mortality and morbidity.

Read More: COPD News and COPD Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.